Shalby Ltd Q3 FY24 Earnings Call Analysis

Future growth expectations for Shalby Limited are as follows: - Hospital business expected to achieve 18-20% annual growth, driven by organic and inorganic expansion. - Occupancy levels to grow 15-18% in existing facilities, with ARPOB (average revenue per occupied bed) increase of 3-6%, resulting in overall 20-22% growth in hospital business. - Inorganic growth opportunities like Sanar Hospital acquisition to add to revenue. - Implant business revenue targeted to maintain or slightly grow, with aggressive Q4 effort to meet prior year's levels. - Implant EBITDA margins expected to be in higher single digits next year and higher double digits in 2-3 years. - Franchise hospital expansion continues; 40 franchise hospitals planned over next 4-5 years. - New territories like Malaysia, Argentina, and Middle East to open for implant sales. - New product launches and increased sales force to drive implant business growth. - Continued focus on operational efficiencies and supply chain optimization to improve margins.

- For the Sanar Hospital acquisition, the funding has been done from internal accruals with Rs.102 Crores already infused. - The company plans a debt-equity mix of 50:50 for further funding related to this acquisition. - Around Rs.70 Crores cash utilization is expected in the next 12 months for working capital and product launches, but the net debt position is expected to remain stable or improve, indicating no significant new debt raising planned beyond this. - There is no mention of any new equity fundraising in the call. - Overall, the company is maintaining a strong balance sheet with low gearing (0.14x group level, 0.02x standalone hospital business). Hence, no immediate large new debt or equity fundraising is indicated, but selective debt utilization and internal accruals are planned for ongoing projects and acquisitions.